Amber Tahir’s Post

#kidneydisease #diseaseprevention #medicine #medicalsciences https://lnkd.in/gxWFy-4x Treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor #empagliflozin slows progression of chronic kidney disease (CKD) across a range of patient characteristics, according to randomized clinical trial data reported in The Lancet Diabetes & Endocrinology. The researchers present a prespecified secondary analysis from the multicenter, international Study of Heart and Kidney Protection with Empagliflozin (EMPA-KIDNEY). In that trial, 6609 patients with CKD were assigned to treatment with empagliflozin (10 mg/day) or placebo. Enrolled patients had an estimated glomerular filtration rate (eGFR) between 20 and 45 mL/min/1.73 m2 or an eGFR between 45 and 90 mL/min/1.73 m2 with a urinary albumin-to-creatinine ratio (UACR) of at least 200 mg/g. The main EMPA-KIDNEY results showed significant reduction in progressive kidney diseases or cardiovascular death among patients assigned to empagliflozin.

Hi, there! This is my new article "Predictors of worsening kidney function and their relation to SGLT2 inhibitor dapagliflozin administration in type 2 diabetes mellitus patients with chronic heart failure" that has been just pablished in the European Journal of Preventive Cardiology

#Semaglutide: Weight loss wonder pill or a threat to health? 🔵 Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily in the treatment of type 2 #diabetes mellitus and in higher doses, being used for weight loss. It mimics the action of endogenous GLP-1, thereby regulating blood glucose levels and exhibiting potential benefits beyond #glycemic control. 🔵 Semaglutide exerts its effects through binding and activation of the GLP-1 receptor, which is predominantly located on pancreatic beta cells. This activation leads to increased glucose-dependent #insulin secretion and suppression of #glucagon secretion. 🔵 Semaglutide has been shown to slow down #gastric emptying, meaning food stays in the stomach longer after ingestion. This effect contributes to its ability to promote feelings of fullness and #satiety. 🔵 Reduction in blood sugar levels: Semaglutide demonstrates superior efficacy in reducing #HbA1c levels compared to diabetic medicines. 🔵 Weight Loss: Clinical trials have consistently shown significant reductions in body weight among patients treated with semaglutide. 🔴 As the food stays longer in the stomach, it can lead to #gastrointestinal discomfort or adverse effects in some individuals. The most common adverse effects of semaglutide therapy include nausea, vomiting, diarrhea, and constipation. 🔴 It can cause intestinal paralysis, also known as paralytic ileus, a rare but serious condition characterized by a temporary loss of normal bowel function. 🔴 #Pancreatitis: Although rare, cases of acute pancreatitis have been reported with the use of GLP-1 receptor agonists, including semaglutide, necessitating vigilance and monitoring in clinical practice. 🔴 #Thyroid C-Cell Tumors: Preclinical studies in rodents have raised concerns about the potential risk of thyroid C-cell #tumors with long-term use of GLP-1 receptor agonists, although the relevance to humans remains uncertain. 🔴 Semaglutide can cause loss of lean mass along with fat mass. Discontinuing the medication could result in the gain of weight lost earlier. And it's likely most of this weight gain is fat, especially in older individuals. 🟢 Why take the risk of potential adverse effects by opting for a shortcut like a pill? Achieving weight loss and reversing diabetes can be effectively attained through a diet consisting of #lowcarb, high-protein, and healthy fats. By steering clear of #sugars, #processed foods, and #refined oils, you're not just enhancing your #health, but also establishing sustainable habits for long term #wellbeing.

#kidneydisease #diabetes #nephrology https://lnkd.in/grh5T-3Y Abstract Diabetic kidney disease (DKD), defined as co-existing #diabetes and chronic kidney disease in the absence of other clear causes of #kidney #injury, occurs in approximately 20–40% of patients with diabetes mellitus. As the global prevalence of diabetes has increased, DKD has become highly prevalent and a leading cause of kidney failure, accelerated cardiovascular disease, premature #mortality and global health care expenditure. Multiple pathophysiological mechanisms contribute to DKD, and single lifestyle or pharmacological interventions have shown limited efficacy at preserving kidney function. For nearly two decades, renin–angiotensin system inhibitors were the only available kidney-protective drugs. However, several new drug classes, including sodium glucose cotransporter-2 inhibitors, a non-steroidal mineralocorticoid antagonist and a selective endothelin receptor antagonist, have now been demonstrated to improve kidney outcomes in people with type 2 diabetes mellitus. In addition, emerging preclinical and clinical evidence of the kidney-protective effects of glucagon-like-peptide-1 receptor agonists has led to the prospective testing of these agents for DKD. Research and clinical efforts are geared towards using therapies with potentially complementary efficacy in combination to safely halt kidney disease progression. As more kidney-protective drugs become available, the outlook for people living with DKD should improve in the next few decades.

For Kidney World Day - to offer our patients optimal medication practice. Diabetic kidney disease (DKD) is a substantial complication of type 2 diabetes (T2D), presenting challenges in chronic kidney disease (CKD) management. In addition to traditional and recent therapies, including angiotensin, converting enzyme (ACE) inhibitors, angiotensin receptor blockers, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists, the evolution of antihyperglycemic treatments has introduced a promising agent, glucagon-like peptide-1 receptor agonist (GLP-1RA) for the management of DKD. The molecular pathways through which GLP1-RA confers renal protection in T2DM and DKD are complex and multifaceted. Our review aims to discuss several mechanisms that have been proposed to explain the renal effects of GLP-1RAs, including direct actions on renal hemodynamics, reduction of systemic and intraglomerular pressure, modulation of tubuloglomerular feedback, inhibition of oxidative stress, inflammation, and fibrosis. These mechanisms highlight GLP1-RA’s potential as a therapeutic option for glycemic control and direct and indirect renal function protection in diabetic patients.

【Diabetes remission】Type 2 diabetes has traditionally been considered an irreversible condition requiring lifelong drug treatment for glucose control. However, recent clinical trials have shown that remission of type 2 diabetes, defined as a return to normal blood glucose levels without the need for drug therapy, can be achieved following sustained weight loss. A CU Medicine study showed that weight loss within the first year after diabetes diagnosis increased the likelihood of achieving diabetes remission. The diabetes and endocrinology research team analysed data from 37,000 population-based patients with newly diagnosed type 2 diabetes in Hong Kong Hospital Authority database and found that compared to those who had gained weight, patients who lost ≥10% of their body weight in the first year after being diagnosed with type 2 diabetes were three times more likely to achieve diabetes remission, while those who lost 5-10% were twice as likely to do so. Although the study demonstrated that diabetes remission was achievable in real-world settings, the overall incidence of diabetes remission was very low -- only 6% of newly diagnosed patients achieved remission in real-world settings during a median follow-up of eight years, translating to a rate of less than 1% per year. The findings have been published in the international medical journal PLOS Medicine. Details: https://bit.ly/3HQ7QYf Full article of study: https://bit.ly/497SU3J #CUMedicine #Diabetes #GlucoseControl

🌊 New Study Alert 🌊 Research from the U.K. Biobank, published in The Journal of Clinical Endocrinology & Metabolism, reveals that patients with type 2 diabetes who regularly consume fish oil have lower risks of vascular complications. 🐟 Higher levels of omega-3 (especially DHA) were linked to fewer macrovascular and microvascular issues, including heart disease and diabetic neuropathy. This reinforces the potential benefits of incorporating fish oil into diabetes care. 🌟 Read more: https://lnkd.in/eU6c3cbK #PharmDLive #DiabetesCare #HeartHealth #Omega3 #FishOil #HealthcareInnovation #VascularHealth #Type2Diabetes #PatientCare #HealthyLiving

Proteomics International is pleased to announce our recent groundbreaking results showing the PromarkerD predictive test can predict renal decline in type 1 diabetes has been published in the peer-reviewed journal of Clinical Diabetes and Endocrinology. The study addresses a significant gap in the medical field, focusing on the lack of prognostic biomarkers for chronic kidney disease in individuals with type 1 diabetes, with the findings presented at the Australasian Diabetes Conference in August. The journal article can be found here - https://lnkd.in/ghNCRJg7 #PIQ #PromarkerD #diabetickidneydisease #dkd #chronickidneydisease #ckd #EarlyDiseaseDetection #prognostics #diagnostics #Biotechnology #HealthcareTechnology #diabetes

From Nature Portfolio Medicine, semaglutide lowered rate of long-term kidney outcomes by 22%, compared to placebo, at four years. These results suggest a benefit of semaglutide on kidney outcomes in individuals with overweight/obesity, without diabetes, with direct kidney protective effects. This data comes from the same SELECT trial that demonstrated that once-weekly subcutaneous semaglutide 2.4 mg was associated with a 20% reduction in major adverse cardiovascular events (MACE) versus placebo. Whilst this data is certainly impressive and meaningful, from a real numbers perspective, there were 43 patients in the semaglutide who avoided the long-term kidney outcomes… from a total sample size of over 8,800 patients on semaglutide in the clinical trial. We would have to treat just over 200 patients on semaglutide, to impact a single patient with respect to improve their outcome of kidney disease. This leads to an economic analysis that I am sure is in process, to reflect on the cost of treating 200 patients over four years, on semaglutide, in comparison to the cost savings of avoiding kidney dialysis and/or kidney transplantation. https://lnkd.in/eNmYAj_s

Turn on the red light again -Photobiomodulation remember this term Photobiomodulation Therapy on the Treatment of Insulin Resistance: A Narrative Review Flávio de Castro Magalhães 1, Cleber Ferraresi 2 Affiliations expand PMID: 36040371 DOI: 10.1089/photob.2022.0031 Abstract Background: Insulin resistance (IR) is the main risk factor for the development of type 2 diabetes mellitus (DM2). Noninvasive and nonpharmacological therapies, such as exercise and diet are effective in treating IR and DM2; however, adherence to them generally is low and diminishes positive effects in the long term. Photobiomodulation therapy (PBMT) is another noninvasive and nonpharmacological therapy, which produces positive effects on mitochondrial metabolism, oxidative stress, and inflammation generally linked to IR and DM2 and may improve or attenuate the severity of these diseases. Objective: In this narrative review, we focus on the available literature related to the effects of PBMT on IR.  Results: In fact, recent in vitro and in vivo studies have demonstrated improvements in IR in skeletal muscle, adipose tissue, and hepatic cells mediated by PBMT. Further, there is evidence that PBMT can potentiate exercise-induced improvement in IR through ameliorating mitochondrial dysfunction, reducing inflammation, and modulating oxidative stress. Moreover, reduced adiposity and altered gut microbiota also appear to mediate PBMT effects on IR. Conclusions: Although these results are exciting, randomized clinical trials are urgently needed to confirm the clinical relevance of PBMT in the treatment of IR. Investigation about the effects of PBMT combined with different volumes of physical exercises may also contribute significantly for those patients having difficulty to adhere to the recommended minimal exercise volume. Finally, studies on PBMT parameters (e.g., dosimetry, wavelengths, single-point vs. full-body irradiation) are also necessary for the appropriate prescription of PBMT for the treatment of IR.